Selventa

Genstruct Extends Collaboration in Cancer with GlaxoSmithKline

Genstruct Extends Collaboration in Cancer with GlaxoSmithKline

August 8, 2006

CAMBRIDGE, Mass., Aug. 8 /PRNewswire/ -- Genstruct Inc., a knowledge- driven discovery company using systems biology to increase the effectiveness of drug discovery and development, announced today that it will begin the second phase of a multi-phase agreement with GlaxoSmithKline plc (NYSE: GSK) (GSK), to jointly investigate compound mechanisms in oncology and to identify biomarkers for patient stratification and drug response.

BG Medicine, Inc.

Philips and BG Medicine Form Alliance for Molecular Medicine Research and Development

Philips and BG Medicine Form Alliance for Molecular Medicine Research and Development

August 11, 2006

Partners to Embark upon Joint Development of Molecular Imaging and Diagnostic Products

Mascoma Corporation

Mascoma Corporation Names Dr. Andrew Richard as CTO, Partners with Dartmouth for Expanded Cellulosic Ethanol Research

Mascoma Corporation Names Dr. Andrew Richard as CTO, Partners with Dartmouth for Expanded Cellulosic Ethanol Research

August 30, 2006

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 30, 2006--Mascoma Corporation, the leader in cellulosic biomass-to-ethanol development and production, today announced the appointment of Dr. Andrew Richard to the position of Chief Technology Officer. In this role Dr. Richard will apply his ethanol industry expertise and advance the company's technology and cellulosic ethanol processes through R&D and into the commercial market.

Adnexus Therapeutics

Adnexus Therapeutics Expands and Strengthens Senior Management Team

Adnexus Therapeutics Expands and Strengthens Senior Management Team

September 5, 2006

Experienced Drug Development Team to Drive Adnectin Product Pipeline and Corporate Development

9/5/2006 10:41:00 AM EST

Adnexus Therapeutics(TM) today announced expansion of its management team to advance corporate and pipeline development. Eric S. Furfine, Ph.D. holds the position of Senior Vice President of Research and Preclinical Development, Charles R. Carter is the company's Vice President, Finance, and Erin E. Lanciani assumes the role Vice President, Human Resources.

Alvine Pharmaceuticals, Inc.

Alvine Pharmaceuticals Closes a $21 Million Series A Financing

Alvine Pharmaceuticals Closes a $21 Million Series A Financing

September 12, 2006

PALO ALTO, Calif. — September 12, 2006 — Alvine Pharmaceuticals, Inc., a biopharmaceutical company focused on developing pharmaceutical products for the treatment of celiac sprue, today announced the closing of a $21 million Series A financing. Sofinnova Ventures led the investment round with strong support from Prospect Venture Partners and InterWest Partners. Cargill Ventures and Flagship Ventures also participated in the financing.

Carbon Design Systems

Carbon Fuels Growth With Additional $5M Funding

Carbon Fuels Growth With Additional $5M Funding

September 14, 2006

Next Generation Product Development Underway

WALTHAM, MA -- (MARKET WIRE) -- 09/14/2006 -- Carbon Design Systems -- an innovator in ESL tools for software validation prior to silicon -- announced today that it has raised $5M in its series D round of financing. In addition, Carbon mentioned that Edgar Masri will remain on its board of directors, after being recently appointed the new president and chief executive officer of 3Com, a leader in networking products.

e-Dialog, Inc.

e-Dialog Becomes First E-mail Service Provider to Achieve ISO 27001 Certification for Information Security

e-Dialog Becomes First E-mail Service Provider to Achieve ISO 27001 Certification for Information Security

September 20, 2006

Standard Validates Company’s Commitment to Best-in-Class Data Security Processes and Maximizing Relevance in E-mail Marketing

Adnexus Therapeutics

Adnexus Therapeutics Appoints L. Patrick Gage, Ph.D., as Chairman of the Board of Directors

Adnexus Therapeutics Appoints L. Patrick Gage, Ph.D., as Chairman of the Board of Directors

September 25, 2006

Widely recognized industry leader to guide company advancing breakthrough class of protein therapeutics

Pervasis Therapeutics, Inc.

Pervasis Therapeutics' Vascugel(TM) Initiates U.S. Clinical Trials Following Successful FDA IND Review

Pervasis Therapeutics' Vascugel(TM) Initiates U.S. Clinical Trials Following Successful FDA IND Review

September 27, 2006

Pioneer in regenerative cell-based therapies and devices begins Phase I trials of first biologically-active treatment to ameliorate acute vascular injury

CGI Pharmaceuticals, Inc.

Genentech and CGI Pharmaceuticals Enter Into Exclusive Global Strategic Alliance for Potential Products in Multiple Oncology and Autoimmune Indications

Genentech and CGI Pharmaceuticals Enter Into Exclusive Global Strategic Alliance for Potential Products in Multiple Oncology and Autoimmune Indications

October 3, 2006

SOUTH SAN FRANCISCO, Calif. and BRANFORD, Conn., Oct. 3 -- Genentech, Inc. (NYSE: DNA - News) and CGI Pharmaceuticals, Inc. announced today that they have entered into an exclusive global collaboration agreement to discover, develop, manufacture and commercialize therapeutics for an undisclosed target for the potential treatment of multiple oncology and autoimmune indications.